CN-122005531-A - Application of oleic acid in medicines for treating atopic dermatitis

Abstract

The application provides application of oleic acid in an atopic dermatitis therapeutic drug, relates to the technical field of biomedicine, and discovers for the first time through a non-targeted metabonomics technology that the level of oleic acid (Oleic Acid, OA) in cells is obviously increased (VIP score > 25) after a peripheral sensory neuron is stimulated by an itching inflammatory factor IL-31, so that free fatty acid metabolism is involved in the regulation of itching and inflammatory signals. Through specific verification experiments, oleic acid can obviously improve symptoms of pruritus model animals and regulate related immune responses at specific concentration, and provides a brand new and low-cost candidate scheme for treating atopic dermatitis.

Inventors

• LU YANAN
• ZHANG ZHIJUN
• BAI XUEQIANG
• GAO ZIYAN
• YANG LIANGCHEN
• XU YICHEN
• SUN JIAYI

Assignees

• 南通大学

Dates

Publication Date

20260512

Application Date

20260204

Claims (10)

1. 1. Use of oleic acid in the preparation of a product for the treatment and/or prevention of itching and inflammatory skin disorders.
2. 2. The method for preparing the product for treating and/or preventing itch and inflammatory disorders of skin according to claim 1, wherein said product is any one of pharmaceutical composition, health product or functional food.
3. 3. The use of oleic acid as claimed in claim 1 for the preparation of a product for the treatment and/or prophylaxis of pruritic and inflammatory skin diseases which are associated with activation of the IL-31 signaling pathway.
4. 4. The use of oleic acid as claimed in claim 1 for the preparation of a product for the treatment and/or prophylaxis of itching and inflammatory skin diseases, characterized in that the route of administration of said product is oral or topical.
5. 5. The use of oleic acid as claimed in claim 4 for the preparation of products for the treatment and/or prophylaxis of itching and inflammatory skin diseases, characterized in that the products are orally administered via drinking water.
6. 6. The use of oleic acid as claimed in claim 1 for the preparation of a product for the treatment and/or prophylaxis of itching and inflammatory skin disorders, characterized in that the medicament further comprises a further pharmaceutically acceptable adjuvant.
7. 7. A product for treating or preventing pruritus and inflammatory dermatoses is characterized by comprising oleic acid.
8. 8. A method for verifying the application of oleic acid in treating or preventing pruritus and inflammatory dermatosis is characterized by comprising in-vivo drug effect verification and in-vitro mechanism verification.
9. 9. The method for verifying the application of oleic acid in treating or preventing itch and inflammatory skin diseases according to claim 8, wherein the in vivo efficacy verification is carried out by adding oleic acid with a certain concentration into drinking water in a MC 903-induced mouse atopic dermatitis itch model, and evaluating the index of the mouse.
10. 10. The method of claim 8, wherein the in vitro mechanism is performed by treating oleic acid in a range of concentrations in the macrophage cell line (RAW 264.7) to detect LPS-induced inflammatory responses without affecting cell viability.

Description

Application of oleic acid in medicines for treating atopic dermatitis Technical Field The application relates to the technical field of biomedicine, in particular to application of oleic acid in a medicament for treating atopic dermatitis. Background Atopic dermatitis (Atopic dermatitis, AD) is a common chronic inflammatory skin disease characterized mainly by dry skin, itching, erythema, exudation etc., severely affecting the quality of life of the patient. Its pathogenesis is closely related to immune disorder, impaired skin barrier function, abnormal secretion of inflammatory factors, etc. The existing clinical therapeutic drugs mainly comprise glucocorticoid, immunosuppressant, antihistamine and the like, but have the problems of obvious side effect, reduced curative effect after long-term use, easy recrudescence and the like. For example, glucocorticoid may cause adverse reactions such as skin atrophy, pigmentation, etc. after long-term use, and immunosuppressants may affect normal immune functions of the body. Therefore, the development of novel safe and effective therapeutic drugs and targets with small side effects has important clinical demands. Disclosure of Invention The application aims to solve the technical problems of obvious side effect, reduced curative effect after long-term use and the like of the medicine for treating atopic dermatitis in the prior art. Use of oleic acid in the preparation of a product for the treatment and/or prevention of itching and inflammatory skin disorders. Preferably, the product is any one of a pharmaceutical composition, a health product or a functional food. Preferably, the pruritic and inflammatory skin conditions are associated with activation of the IL-31 signaling pathway. Preferably, the route of administration of the product is oral or topical. Preferably, the product is administered orally through drinking water. Preferably, the medicament further comprises other auxiliary agents which are acceptable in medicine. The application also provides a product for treating or preventing itch and inflammatory skin diseases, wherein the product comprises oleic acid. The application also provides a method for verifying the application of oleic acid in treating or preventing pruritus and inflammatory dermatosis, comprising in-vivo efficacy verification and in-vitro mechanism verification. Preferably, the in vivo efficacy verification evaluates the index of the mice by adding a certain concentration of oleic acid to drinking water in the MC 903-induced atopic dermatitis pruritus model of the mice. Preferably, the in vitro mechanism verifies that LPS-induced inflammatory responses are detected by oleic acid treatment in a range of concentrations in the macrophage cell line (RAW 264.7) without affecting cell viability. Compared with the prior art, the application at least comprises the following beneficial effects: 1. The verification test proves that the oral administration of low-dose oleic acid can clearly improve the appearance of skin inflammation and the core symptoms of itch (scratching behavior) in a atopic dermatitis animal disease model, and the effect is remarkable. 2. The application relates the oleic acid level change with the itching inflammatory factor IL-31 signal for the first time, and confirms the anti-inflammatory and antipruritic effects of oleic acid, thereby providing direct evidence for targeted fatty acid metabolism treatment of itching. 3. Because oleic acid is a naturally occurring fatty acid, the composition has good human tolerance, high safety as a component of a medicine or a health care product, easily obtained raw materials and low production cost. Drawings FIG. 1 shows the molecular structural formula of oleic acid. FIG. 2 is a flow chart of a non-targeted metabonomics analysis and IL-31 stimulation of sensory neurons induced significant increases in Oleic Acid (OA), palmitic Acid (PA), etc. (A) Cell processing, metabolite extraction, LC-MS analysis and data processing. (B) Principal Component Analysis (PCA) plots showed good intra-group reproducibility. (C) differential metabolite VIP score table highlighting OA and PA. FIG. 3 shows the improvement of skin inflammatory phenotype in MC903 model mice by oral Oleic Acid (OA). Comparison of representative photographs of facial skin of the Vehicle group and the OA group of MC903 model mice on days 4, 6, and 8 shows a reduction in skin inflammation in the OA group. Fig. 4 is a graph showing that oral Oleic Acid (OA) can alleviate the itching behavior of MC903 model mice. Wherein (A) quantitative statistical plot of spontaneous scratching behavior during addition of OA in MC903 mice drinking water shows a reduced number of scratches in the OA group. (B) mice body weight change profile during the experiment. FIG. 5 shows that oral Oleic Acid (OA) can regulate expression of skin inflammatory factors in MC903 model mice. mRNA relative expression levels of IL-6, TNF- α, CD206 in skin tissue wer